GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.

Purpose: To find genetic variants that predicted toxicity and/or efficacy of paclitaxel plus carboplatin combination therapy (TC therapy).
Patients and Methods: In a retrospective case-control study, we analyzed 320 patients who had received TC therapy for gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, and cervical cancers) and collected their germline DNA. We performed a comprehensive pharmacogenomic analysis using a targeted resequencing panel of 100 pharmacogenes. For 1,013 variants passing QC, case-control association studies and survival analyses were conducted.
Results: GSTP1 rs1695 showed the smallest p value for hematotoxicity association, and the ¹⁰⁵ Ile wild type allele had a significantly higher risk of severe hematotoxicity (neutropenia G4, thrombocytopenia ≥ G3 and anemia ≥ G3) than the ¹⁰⁵ Val allele (p=0.00034, odds ratio=5.71 (95% confidence interval:1.77-18.44)). Next, we assessed 5-year progression-free survival (PFS) and overall survival (OS) in 56 advanced ovarian cancer patients who received tri-weekly TC as a first-line chemotherapy. Patients with the ¹⁰⁵ Ile/ ¹⁰⁵ Ile genotype showed significantly better PFS (p=0.00070) and OS (p=0.0012) than those with the ¹⁰⁵ Ile/ ¹⁰⁵ Val or ¹⁰⁵ Val/ ¹⁰⁵ Val genotype.
Conclusion: Our study indicates that the GSTP1 rs1695 ¹⁰⁵ Ile/ ¹⁰⁵ Ile genotype is associated with both severe hematotoxicity and high efficacy of TC therapy, identifying a possible prognostic indicator for patients with TC therapy.
Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.